• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Research Articles Abstracts?April 19 2014 Issue

Giuseppe

Giuseppe

Emeritus
[Source: AMEDEO, homepage: (LINK).]


Research Articles Abstracts?April 19 2014 Issue
_____

This week?s Abstracts:
__

  • BMJ
  • Cell
    • MILLER MS, Palese P
  • J Gen Virol
    • EL-SHESHENY R, Kandeil A, Bagato O, Maatouq AM, et al
      • Molecular characterization of avian influenza H5N1 virus in Egypt and the emergence of a novel endemic sub-clade.
  • J Infect Dis
    • BIGGERSTAFF M, Jhung MA, Reed C, Fry AM, et al
      • Influenza-like illness, the time to seek healthcare, and influenza antiviral receipt during the 2010-11 influenza season -- United States.
    • LINDEGREN ML, Schaffner W
      • Treatment with Neuraminidase Inhibitors for High Risk Patients with influenza: Why is adherence to antiviral treatment recommendations so low?
  • J Virol
    • REUTHER P, Giese S, Gotz V, Riegger D, et al
      • Phosphorylation of highly conserved serine residues in the influenza A virus nuclear export protein NEP plays a minor role in viral growth in human cells and mice.
    • TAO H, Steel J, Lowen AC
    • CAO S, Jiang J, Li J, Li Y, et al
      • Characterization of The Nucleocytoplasmic Shuttle of The Matrix Protein of Influenza B Virus.
    • GAO S, Wang S, Cao S, Sun L, et al
      • The characteristics of nucleocytoplasmic transport of H1N1 influenza A viruses nuclear export protein (NEP).
  • PLoS One
    • NTSHOE GM, McAnerney JM, Tempia S, Blumberg L, et al
      • Influenza Epidemiology and Vaccine Effectiveness among Patients with Influenza-Like Illness, Viral Watch Sentinel Sites, South Africa, 2005-2009.
    • ?
      • Correction: Pretreatment of Epithelial Cells with Live Streptococcus pneumoniae Has No Detectable Effect on Influenza A Virus Replication In Vitro.
    • MESQUITA M, Resende P, Marttorelli A, Machado V, et al
      • Detection of the Influenza A(H1N1)pdm09 Virus Carrying the K-15E, P83S and Q293H Mutations in Patients Who Have Undergone Bone Marrow Transplant.
    • TONG HH, Lambert G, Li YX, Thurman JM, et al
      • Deletion of the Complement C5a Receptor Alleviates the Severity of Acute Pneumococcal Otitis Media following Influenza A Virus Infection in Mice.
    • ?
      • Correction: identification and chronological analysis of genomic signatures in influenza a viruses.
    • XIE Z, Huang J, Luo S, Xie Z, et al
      • Ultrasensitive electrochemical immunoassay for avian influenza subtype h5 using nanocomposite.
  • Proc Natl Acad Sci U S A
    • CONNARIS H, Govorkova EA, Ligertwood Y, Dutia BM, et al
      • Prevention of influenza by targeting host receptors using engineered proteins.
  • Vaccine
    • LU PJ, O'Halloran A, Ding H, Williams WW, et al
      • National and state-specific estimates of place of influenza vaccination among adult populations - United States, 2011-12 influenza season.
    • NEUHAUS V, Chichester JA, Ebensen T, Schwarz K, et al
      • A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    • TABYNOV K, Kydyrbayev Z, Ryskeldinova S, Assanzhanova N, et al
      • Duration of the protective immune response after prime and booster vaccination of yearlings with a live modified cold-adapted viral vaccine against equine influenza.
  • Virology
    • NOISUMDAENG P, Pooruk P, Prasertsopon J, Assanasen S, et al
      • Homosubtypic and heterosubtypic antibodies against highly pathogenic avian influenza H5N1 recombinant proteins in H5N1 survivors and non-H5N1 subjects.
    • KUKOL A, Hughes DJ
      • Large-scale analysis of influenza A virus nucleoprotein sequence conservation reveals potential drug-target sites.
    • KELVIN AA, Degousee N, Banner D, Stefanski E, et al
      • Lack of group X secreted phospholipase A2 increases survival following pandemic H1N1 influenza infection.
    • LU X, Liu F, Zeng H, Sheu T, et al
      • Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
  • Virus Res
    • METREVELI G, Gao Q, Mena N, Schmolke M, et al
      • The origin of the PB1 segment of swine influenza A virus subtype H1N2 determines viral pathogenicity in mice.
-
------
 
Re: Research Articles Abstracts?April 19 2014 Issue

## Giuseppe had it already with link. I tried pnas-website before , but didn't find it

The method, successfully tested only in mice thus far, is a nasal spray of engineered
proteins that coat the receptors in the nose and throat to which flu viruses attach.
can be grown in E. coli,
"We think it has potential," said co-author Dr. Robert G. Webster
A new drug, Fludase, is being tested. It chops up the same receptors that the new proteins block.
Presumably the receptors evolved to attach to something that benefits the cells, but it is unclear what.
Cells replace the receptors quickly, he said, so blocking them for a week to ward off flu does
not appear harmful.
only for prevention, not for treatment
Give it to the mice even one day after infection, and it does diddly-squat
in PNAS next Monday

## from my experience with researchers, if they really considered it important, they would
## have tested it in ferrets by themselves before publishing --> some evidence that it doesn't
work in ferrets]


http://www.businessghana.com/portal/news/index.php?op=getNews&news_cat_id=1&id=197677


http://www.ncbi.nlm.nih.gov/pubmed/24733924

multivalent biologics, engineered using carbohydrate-binding modules specific
for sialic acid, mask the cell-surface receptor recognized by flu and protect
mice from a lethal challenge with ******.

## how do they know it masks the cell surface ? It could also maybe go into the mucus
## but virus-NA cleaves

The most promising biologic protects mice when given as a single intranasal
dose 7 d in advance of .
There also is sufficient virus replication to establish an immune response,
potentially protecting the animal from future exposure to the virus.

## give the spray, then infect with a real , normal flu so to create longer lasting,
## real immunity with low probability of real symptomatic infection
## so some viruses presumably still enter cells and replicate
## or the spray only protects certain cells

Furthermore, the biologics appear to stimulate inflammatory mediators,
and this stimulation may contribute to their protective ability.

## or maybe this is the only effect, giving the whole protection ?
 
You must log in or register to reply here.
Back
Top